A placebo-controlled, dose-finding, phase II trial testing the efficacy and safety of BG00012, an oral formulation of dimethyl fumarate, reports a reduced incidence of gadolinium-enhancing lesions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback